← Eichor
Study identifier: NCT07243782 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

Condition: Hidradenitis Suppurativa · Pediatric Plaque Psoriasis · Juvenile Idiopathic Arthritis  ·  Sponsor: Novartis Pharmaceuticals

PhaseN/A
Planned participants76
Who can joinAll sexes, 6 Years to 100 Years
Healthy volunteersNo

About this study

Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals  ·  +41613241111  ·  novartis.email@novartis.com

Novartis Pharmaceuticals

Always discuss trial participation with your own doctor first.

Locations (1)

Novartis Investigative SiteSeoul, Seoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07243782